Vertex Urged To Target Major M&A After Another Rare Disease Failure
Slip-Up Good News For Arrowhead
Executive Summary
After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.